This book explores the controversial relationship between physicians and the pharmaceutical industry, identifies the ethical tensions and controversies, and proposes numerous reforms both for medicine's own professional integrity and for effective public regulation of the industry.
This book explores the controversial relationship between physicians and the pharmaceutical industry, identifies the ethical tensions and controversies, and proposes numerous reforms both for medicine's own professional integrity and for effective public regulation of the industry.
Chapter 1 Introduction: The Tipping Point Part 2 I. Overview Chapter 3 1. The Good, the Bad, and the Ugly: A Story of Two Medications Chapter 4 2. An Ethical Framework Part 5 II. Specific Issues and Problems Chapter 6 3. The Pharmaceutical Industry and the Free Market Chapter 7 4. Patents, Generic Drugs, and Academic Science Chapter 8 5. Research and Profits Chapter 9 6. Suppression of Research Data Chapter 10 7. The Quality of Pharmaceutical Research Chapter 11 8. The Drug Rep: Historical Background Chapter 12 9. The Drug Rep Today Chapter 13 10. The Influence of Drug Reps: What the Data Show Chapter 14 11. Continuing Medical Education Chapter 15 12. Professional Organizations and Journal Advertising Chapter 16 13. The Industry and the Consumer Chapter 17 14. The FDA: From Patent Medicine to AIDS Drugs Chapter 18 15. The FDA and the Industry, 1990-2004 Part 19 III. Toward Solutions Chapter 20 16. Solutions: The Management and Divestment Strategies Chapter 21 17. Solutions Requiring Enhanced Professionalism in Medicine Chapter 22 18. Solutions Requiring Regulatory Reform Chapter 23 Epilogue: Industry Woes and Professional Opportunities
Chapter 1 Introduction: The Tipping Point Part 2 I. Overview Chapter 3 1. The Good, the Bad, and the Ugly: A Story of Two Medications Chapter 4 2. An Ethical Framework Part 5 II. Specific Issues and Problems Chapter 6 3. The Pharmaceutical Industry and the Free Market Chapter 7 4. Patents, Generic Drugs, and Academic Science Chapter 8 5. Research and Profits Chapter 9 6. Suppression of Research Data Chapter 10 7. The Quality of Pharmaceutical Research Chapter 11 8. The Drug Rep: Historical Background Chapter 12 9. The Drug Rep Today Chapter 13 10. The Influence of Drug Reps: What the Data Show Chapter 14 11. Continuing Medical Education Chapter 15 12. Professional Organizations and Journal Advertising Chapter 16 13. The Industry and the Consumer Chapter 17 14. The FDA: From Patent Medicine to AIDS Drugs Chapter 18 15. The FDA and the Industry, 1990-2004 Part 19 III. Toward Solutions Chapter 20 16. Solutions: The Management and Divestment Strategies Chapter 21 17. Solutions Requiring Enhanced Professionalism in Medicine Chapter 22 18. Solutions Requiring Regulatory Reform Chapter 23 Epilogue: Industry Woes and Professional Opportunities
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
